| HOME >> BIOLOGY >> TECHNOLOGY |
a and an established global regulatory and commercial
organization.
-- Sales of Aldurazyme(R) (laronidase) increased 38 percent to $37.0
million in the first quarter, compared with $26.8 million in the same
quarter a year ago. Genzyme now records sales of Aldurazyme on its top
line and makes tiered payments to BioMarin Pharmaceutical Inc. on
worldwide product sales under a restructured agreement between the
companies.
-- Sales of Thyrogen(R) (thyrotropin alfa for injection) grew 28 percent
in the first quarter to $33.8 million from $26.3 million, reflecting
ongoing improvement in thyroid cancer detection and well-established
treatment guidelines. The use of Thyrogen in ablation procedures is
also contributing to the product's growth, following the December 2007
U.S. approval for this indication.
-- Within the Renal business, sales of sevelamer therapies Renagel(R)
(sevelamer hydrochloride) and Renvela grew 23 percent to $168.7 million
from $137.4 million in the first quarter last year. In March, Genzyme
launched Renvela in the United States, where the company is engaged in
active discussions with the FDA to expand the product's labeling to
include chronic kidney disease patients with hyperphosphatemia who are
not on dialysis. The three companies that currently market phosphate
binders are working collaboratively to provide the FDA with information
that will help the agency determine the appropriate treatment paradigm
for these patients. Genzyme anticipates that the Renvela label
expansion will take place at the latest by the middle of 2009. Genzyme
has also filed for European approval for Renvela in both the dialysis
and chronic kidney disease indications.
-- Within the Transplant business, first-quarter sales of Thymoglobulin(R)
'/>"/>
| SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |